ReviewJournal of enzyme inhibition and medicinal chemistry2026
New insights into the ACLY-mediated metabolic and epigenetic interplay in macrophages.
Review in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Macrophages are plastic innate immune cells that polarize into pro-inflammatory M1 or anti-inflammatory M2 phenotypes in response to microenvironmental signals, with their dynamic balance governing inflammation resolution and tissue homeostasis. This polarization entails profound metabolic reprogramming, wherein ATP-citrate lyase (ACLY) acts as a key regulator. By controlling intracellular acetyl-CoA production, ACLY modulates histone acetylation and chromatin remodeling, thereby influencing the expression of inflammation-related genes. This review systematically outlines ACLY's structural features and elucidates its core mechanisms that integrate metabolic and epigenetic cues to orchestrate macrophage polarization and inflammatory responses. In addition, it summarizes the pharmacological properties and clinical translational potential of ACLY inhibitors, highlighting their promise as therapeutic agents. Collectively, this work aims to offer novel theoretical insights and intervention strategies for targeting macrophage immunometabolism in chronic inflammation and associated metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.